Novel pharmacological perspectives in radiotherapy

dc.contributor.advisorPórszász, Róbert
dc.contributor.advisordeptDebreceni Egyetem::Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézethu_HU
dc.contributor.authorBánffy, Balázs
dc.contributor.departmentDE--Általános Orvostudományi Karhu_HU
dc.contributor.opponentDrimba, László
dc.contributor.opponentSzentmiklósi, József András
dc.contributor.opponentdeptKenézy Kórház Központi Aneszteziológiai és Intenzív Terápiás Osztályhu_HU
dc.contributor.opponentdeptDebreceni Egyetem::Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézethu_HU
dc.date.accessioned2019-01-30T12:37:46Z
dc.date.available2019-01-30T12:37:46Z
dc.date.created2018
dc.description.abstractRadiotherapy is an integral part of oncotherapy, usually used in combination with surgical therapy and/or chemotherapy in order to enhance the overall effect. Anti-cancer drugs have been continuously developed parallel with the widening of our molecular understanding of cancer biology. The substitution of current conventional agents used in everyday practice to modern radio enhancers is one of the main objectives is clinical oncology. At the present time these newer radiosensitisers such as metal-oxide nanoparticles, compounds with wide cross-section for neutron capture, hypothetical hybrid particles and gadolinium-based agents are being used particularly in preclinical or early-clinical studies.hu_HU
dc.description.correctorSZG
dc.description.correctorLB
dc.description.courseáltalános orvoshu_HU
dc.description.courseactnappalihu_HU
dc.description.courselangmagyarhu_HU
dc.description.degreeegységes, osztatlanhu_HU
dc.format.extent50hu_HU
dc.identifier.urihttp://hdl.handle.net/2437/263434
dc.language.isoenhu_HU
dc.subjectradiotherapyhu_HU
dc.subjectquantum hit theory
dc.subjectnanoparticle
dc.subjectHafnium nanoparticle
dc.subject.dspaceDEENK Témalista::Orvostudomány::Onkológiahu_HU
dc.titleNovel pharmacological perspectives in radiotherapyhu_HU
Fájlok